# A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

> **NCT05331300** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lassen Therapeutics 1 PTY LTD** · enrollment: 75 (actual)

## Conditions studied

- Pulmonary Fibrosis
- Thyroid Eye Disease

## Interventions

- **DRUG:** LASN01
- **DRUG:** LASN01
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05331300
- **Lead sponsor:** Lassen Therapeutics 1 PTY LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-06
- **Primary completion:** 2024-11-27
- **Final completion:** 2024-11-27
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05331300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05331300, "A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT05331300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*